Phosphodiesterase 2 Protects Against Catecholamine-Induced Arrhythmia and Preserves Contractile Function after Myocardial Infarction

Circulation Research

Volumn 120, Issue 1, 2017, Pages 120-132

  Vettel, Christiane ^a,b,j   Lindner, Marta ^c   Dewenter, Matthias ^b,d,j   Lorenz, Kristina ^e   Schanbacher, Constanze ^e   Riedel, Merle ^b,j   Lämmle, Simon ^f   Meinecke, Simone ^b,j   Mason, Fleur E ^b,j   Sossalla, Samuel ^b,g,j   Geerts, Andreas ^h   Hoffmann, Michael ^h   Wunder, Frank ^h   Brunner, Fabian J ^i,j   Wieland, Thomas ^a,j   Mehel, Hind ^c   Karam, Sarah ^c   Lechêne, Patrick ^c   Leroy, Jérôme ^c   Vandecasteele, Grégoire ^c   Wagner, Michael ^f   Fischmeister, Rodolphe ^c   El Armouche, Ali ^f   more..

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

^c INSERM   (France)

^d UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^e UNIVERSITY OF WÜRZBURG   (Germany)

^f DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^g UNIVERSITY OF KIEL   (Germany)

^h BAYER PHARMA AG   (Germany)

ⁱ UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^j DZHK GERMAN CENTRE FOR CARDIOVASCULAR RESEARCH   (Germany)

more..

Author keywords

cardiac arrhythmia; catecholamine; cyclic GMP stimulated phosphodiesterase; heart rate; myocardial contraction

Indexed keywords

BAY 60 7550; CATECHOLAMINE; CYCLIC AMP; DOBUTAMINE; ISOPRENALINE; IVABRADINE; METOPROLOL; PHOSPHODIESTERASE; PHOSPHODIESTERASE 2; PHOSPHODIESTERASE INHIBITOR; RYANODINE RECEPTOR 2; UNCLASSIFIED DRUG; 2-(3,4-DIMETHOXYBENZYL)-7-(1-(1-HYDROXYETHYL)-4-PHENYLBUTYL)-5-METHYLIMIDAZO(5,1-F)(1,2,4)TRIAZIN-4 (3H)-ONE; CARDIOTONIC AGENT; CYCLIC NUCLEOTIDE PHOSPHODIESTERASE 2; IMIDAZOLE DERIVATIVE; TRIAZINE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CARDIAC MUSCLE CELL; CHRONOTROPISM; CONTROLLED STUDY; DRUG DOSE INCREASE; ELECTROCARDIOGRAM; ENZYME INHIBITION; HEART ARRHYTHMIA; HEART INFARCTION; HEART MUSCLE CONTRACTILITY; HEART OUTPUT; HEART PROTECTION; HEART RATE; HEART RATE VARIABILITY; HEART VENTRICLE ARRHYTHMIA; IN VIVO STUDY; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RR INTERVAL; TELEMETRY; ANIMAL; ANTAGONISTS AND INHIBITORS; ARRHYTHMIAS, CARDIAC; BIOSYNTHESIS; CHEMICALLY INDUCED; DOG; DRUG EFFECTS; FEMALE; HEART CONTRACTION; MALE; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY; TRANSGENIC MOUSE;

ANIMALS; ARRHYTHMIAS, CARDIAC; CARDIOTONIC AGENTS; CATECHOLAMINES; CYCLIC NUCLEOTIDE PHOSPHODIESTERASES, TYPE 2; DOGS; FEMALE; IMIDAZOLES; ISOPROTERENOL; MALE; MICE; MICE, TRANSGENIC; MYOCARDIAL CONTRACTION; MYOCARDIAL INFARCTION; TRIAZINES;

EID: 84994662820     PISSN: 00097330     EISSN: 15244571     Source Type: Journal    
DOI: 10.1161/CIRCRESAHA.116.310069     Document Type: Article

References (58)

1. Cohn JN, Levine TB, Olivari MT, Garberg V, Lura D, Francis GS, Simon AB, Rector T. Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. N Engl J Med. 1984;311:819-823. doi: 10.1056/NEJM198409273111303.
2. Tomaselli GF, Zipes DP. What causes sudden death in heart failure? Circ Res. 2004;95:754-763. doi: 10.1161/01.RES.0000145047.14691.db.
3. Coronel R, Wilders R, Verkerk AO, Wiegerinck RF, Benoist D, Bernus O. Electrophysiological changes in heart failure and their implications for arrhythmogenesis. Biochim Biophys Acta. 2013;1832:2432-2441. doi: 10.1016/j.bbadis.2013.04.002.
4. Fox K, Ford I, Steg PG, Tendera M, Robertson M, Ferrari R; BEAUTIFUL investigators. Heart rate as a prognostic risk factor in patients with coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a subgroup analysis of a randomised controlled trial. Lancet. 2008;372:817-821. doi: 10.1016/S0140-6736(08)61171-X.
5. Bilchick KC, Berger RD. Heart rate variability. J Cardiovasc Electrophysiol. 2006;17:691-694. doi: 10.1111/j.1540-8167.2006.00501.x.
6. Bristow MR, Ginsburg R, Minobe W, Cubicciotti RS, Sageman WS, Lurie K, Billingham ME, Harrison DC, Stinson EB. Decreased catecholamine sensitivity and beta-adrenergic-receptor density in failing human hearts. N Engl J Med. 1982;307:205-211. doi: 10.1056/NEJM198207223070401.
7. Nikolaev VO, Moshkov A, Lyon AR, Miragoli M, Novak P, Paur H, Lohse MJ, Korchev YE, Harding SE, Gorelik J. Beta2-adrenergic receptor redistribution in heart failure changes cAMP compartmentation. Science. 2010;327:1653-1657. doi: 10.1126/science.1185988.
8. El-Armouche A, Eschenhagen T. Beta-adrenergic stimulation and myocar-dial function in the failing heart. Heart Fail Rev. 2009;14:225-241. doi: 10.1007/s10741-008-9132-8.
9. Tilley DG, Rockman HA. Role of beta-adrenergic receptor signaling and desensitization in heart failure: new concepts and prospects for treatment. Expert Rev Cardiovasc Ther. 2006;4:417-432. doi: 10.1586/14779072.4.3.417.
10. Bristow MR. Pathophysiologic and pharmacologic rationales for clinical management of chronic heart failure with beta-blocking agents. Am J Cardiol. 1993;71:12C-22C.
11. Effect of metoprolol CR/XL in chronic heart failure: metoprolol CR/XL randomised intervention trial in congestive heart failure (MERIT-HF). Lancet. 1999;353:2001-2007.
12. Flannery G, Gehrig-Mills R, Billah B, Krum H. Analysis of randomized controlled trials on the effect of magnitude of heart rate reduction on clinical outcomes in patients with systolic chronic heart failure receiving beta-block-ers. Am J Cardiol. 2008;101:865-869. doi: 10.1016/j.amjcard.2007.11.023.
13. Swedberg K, Komajda M, Böhm M, Borer JS, Ford I, Dubost-Brama A, Lerebours G, Tavazzi L; SHIFT Investigators. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet. 2010;376:875-885. doi: 10.1016/S0140-6736(10)61198-1.
14. Walker MJ, Curtis MJ, Hearse DJ, Campbell RW, Janse MJ, Yellon DM, Cobbe SM, Coker SJ, Harness JB, Harron DW. The Lambeth Conventions: guidelines for the study of arrhythmias in ischaemia infarction, and reper-fusion. Cardiovasc Res. 1988;22:447-455.
15. Lee DI, Vahebi S, Tocchetti CG, Barouch LA, Solaro RJ, Takimoto E, Kass DA. PDE5A suppression of acute beta-adrenergic activation requires modulation of myocyte beta-3 signaling coupled to PKG-mediated troponin I phosphorylation. Basic Res Cardiol. 2010;105:337-347. doi: 10.1007/s00395-010-0084-5.
16. Lee DI, Zhu G, Sasaki T, et al. Phosphodiesterase 9A controls nitric-oxide-independent cGMP and hypertrophic heart disease. Nature. 2015;519:472-476. doi: 10.1038/nature14332.
17. Nagayama T, Hsu S, Zhang M, Koitabashi N, Bedja D, Gabrielson KL, Takimoto E, Kass DA. Sildenafl stops progressive chamber, cellular, and molecular remodeling and improves calcium handling and function in hearts with pre-existing advanced hypertrophy caused by pressure overload. J Am Coll Cardiol. 2009;53:207-215. doi: 10.1016/j. jacc.2008.08.069.
18. Wang H, Kohr MJ, Traynham CJ, Ziolo MT. Phosphodiesterase 5 restricts NOS3/soluble guanylate cyclase signaling to L-type Ca2+ current in cardiac myocytes. J Mol Cell Cardiol. 2009;47:304-314. doi: 10.1016/j. yjmcc.2009.03.021.
19. Mika D, Leroy J, Vandecasteele G, Fischmeister R. PDEs create local domains of cAMP signaling. J Mol Cell Cardiol. 2012;52:323-329. doi: 10.1016/j.yjmcc.2011.08.016.
20. Martinez SE, Wu AY, Glavas NA, Tang XB, Turley S, Hol WG, Beavo JA. The two GAF domains in phosphodiesterase 2A have distinct roles in dimerization and in cGMP binding. Proc Natl Acad Sci USA. 2002;99:13260-13265. doi: 10.1073/pnas.192374899.
21. Wu AY, Tang XB, Martinez SE, Ikeda K, Beavo JA. Molecular determinants for cyclic nucleotide binding to the regulatory domains of phosphodiesterase 2A. J Biol Chem. 2004;279:37928-37938. doi: 10.1074/jbc. M404287200.
22. Martinez SE, Beavo JA, Hol WG. GAF domains: two-billion-year-old molecular switches that bind cyclic nucleotides. Mol Interv. 2002;2:317-323. doi: 10.1124/mi.2.5.317.
23. Dittrich M, Jurevicius J, Georget M, Rochais F, Fleischmann B, Hescheler J, Fischmeister R. Local response of L-type Ca(2+) current to nitric oxide in frog ventricular myocytes. J Physiol. 2001;534:109-121.
24. Vandecasteele G, Verde I, Rücker-Martin C, Donzeau-Gouge P, Fischmeister R. Cyclic GMP regulation of the L-type Ca(2+) channel current in human atrial myocytes. J Physiol. 2001;533:329-340.
25. Mongillo M, Tocchetti CG, Terrin A, Lissandron V, Cheung YF, Dostmann WR, Pozzan T, Kass DA, Paolocci N, Houslay MD, Zaccolo M. Compartmentalized phosphodiesterase-2 activity blunts beta-adrenergic cardiac inotropy via an NO/cGMP-dependent pathway. Circ Res. 2006;98:226-234. doi: 10.1161/01.RES.0000200178.34179.93.
26. MacFarland RT, Zelus BD, Beavo JA. High concentrations of a cGMP-stim-ulated phosphodiesterase mediate ANP-induced decreases in cAMP and steroidogenesis in adrenal glomerulosa cells. J Biol Chem. 1991;266:136-142.
27. Ding B, Abe J, Wei H, Huang Q, Walsh RA, Molina CA, Zhao A, Sadoshima J, Blaxall BC, Berk BC, Yan C. Functional role of phosphodiesterase 3 in cardiomyocyte apoptosis: implication in heart failure. Circulation. 2005;111:2469-2476. doi: 10.1161/01.CIR.0000165128.39715.87.
28. Abi-Gerges A, Richter W, Lefebvre F, Mateo P, Varin A, Heymes C, Samuel JL, Lugnier C, Conti M, Fischmeister R, Vandecasteele G. Decreased expression and activity of cAMP phosphodiesterases in cardiac hypertrophy and its impact on beta-adrenergic cAMP signals. Circ Res. 2009;105:784-792. doi: 10.1161/CIRCRESAHA.109.197947.
29. Mehel H, Emons J, Vettel C, et al. Phosphodiesterase-2 is up-regulated in human failing hearts and blunts p-adrenergic responses in cardiomyocytes. J Am Coll Cardiol. 2013;62:1596-1606. doi: 10.1016/j.jacc.2013.05.057.
30. Subramaniam A, Jones WK, Gulick J, Wert S, Neumann J, Robbins J. Tissue-specifc regulation of the alpha-myosin heavy chain gene promoter in transgenic mice. J Biol Chem. 1991;266:24613-24620.
31. Börner S, Schwede F, Schlipp A, Berisha F, Calebiro D, Lohse MJ, Nikolaev VO. FRET measurements of intracellular cAMP concentrations and cAMP analog permeability in intact cells. Nat Protoc. 2011;6:427-438. doi: 10.1038/nprot.2010.198.
32. Klarenbeek J, Goedhart J, van Batenburg A, Groenewald D, Jalink K. Fourth-generation epac-based FRET sensors for cAMP feature exceptional brightness, photostability and dynamic range: characterization of dedicated sensors for FLIM, for ratiometry and with high affnity. PLoS One. 2015;10:e0122513. doi: 10.1371/journal.pone.0122513.
33. 2+ current and protects against ventricular arrhythmias in mice. J Clin Invest. 2011;121:2651-2661. doi: 10.1172/JCI44747.
34. Boess FG, Hendrix M, van der Staay FJ, Erb C, Schreiber R, van Staveren W, de Vente J, Prickaerts J, Blokland A, Koenig G. Inhibition of phosphodiesterase 2 increases neuronal cGMP, synaptic plasticity and memory performance. Neuropharmacology. 2004;47:1081-1092. doi: 10.1016/j. neuropharm.2004.07.040.
35. Masood A, Huang Y, Hajjhussein H, Xiao L, Li H, Wang W, Hamza A, Zhan CG, O'Donnell JM. Anxiolytic effects of phosphodiesterase-2 inhibitors associated with increased cGMP signaling. J Pharmacol Exp Ther. 2009;331:690-699. doi: 10.1124/jpet 109.156729.
36. Davis J, Maillet M, Miano JM, Molkentin JD. Lost in transgenesis: a user's guide for genetically manipulating the mouse in cardiac research. Circ Res. 2012;111:761-777. doi: 10.1161/CIRCRESAHA.111.262717.
37. Hayano J, Sakakibara Y, Yamada A, Yamada M, Mukai S, Fujinami T, Yokoyama K, Watanabe Y, Takata K. Accuracy of assessment of cardiac vagal tone by heart rate variability in normal subjects. Am J Cardiol. 1991;67:199-204.
38. Schweizer PA, Duhme N, Thomas D, Becker R, Zehelein J, Draguhn A, Bruehl C, Katus HA, Koenen M. cAMP sensitivity of HCN pacemaker channels determines basal heart rate but is not critical for autonomic rate control. Circ Arrhythm Electrophysiol. 2010;3:542-552. doi: 10.1161/ CIRCEP.110.949768.
39. Wittköpper K, Fabritz L, Neef S, Ort KR, Grefe C, Unsöld B, Kirchhof P, Maier LS, Hasenfuss G, Dobrev D, Eschenhagen T, El-Armouche A. Constitutively active phosphatase inhibitor-1 improves cardiac contractility in young mice but is deleterious after catecholaminergic stress and with aging. J Clin Invest. 2010;120:617-626. doi: 10.1172/JCI40545.
40. Neef S, Maier LS. Novel aspects of excitation-contraction coupling in heart failure. Basic Res Cardiol. 2013;108:360. doi: 10.1007/ s00395-013-0360-2.
41. Respress JL, van Oort RJ, Li N, et al. Role of RyR2 phosphorylation at S2814 during heart failure progression. Circ Res. 2012;110:1474-1483. doi: 10.1161/CIRCRESAHA.112.268094.
42. van Oort RJ, McCauley MD, Dixit SS, Pereira L, Yang Y, Respress JL, Wang Q, De Almeida AC, Skapura DG, Anderson ME, Bers DM, Wehrens XH. Ryanodine receptor phosphorylation by calcium/calmodulin-depen-dent protein kinase II promotes life-threatening ventricular arrhythmias in mice with heart failure. Circulation. 2010;122:2669-2679. doi: 10.1161/ CIRCULATIONAHA.110.982298.
43. DiFrancesco D. The role of the funny current in pacemaker activity. Circ Res. 2010;106:434-446. doi: 10.1161/CIRCRESAHA.109.208041.
44. Lakatta EG, Maltsev VA , Vinogradova TM. A coupled SYSTEM of intracellular Ca2+ clocks and surface membrane voltage clocks controls the timekeeping mechanism of the heart's pacemaker. Circ Res. 2010;106:659-673. doi: 10.1161/CIRCRESAHA.109.206078.
45. Lyashkov AE, Vinogradova TM, Zahanich I, Li Y, Younes A, Nuss HB, Spurgeon HA, Maltsev VA, Lakatta EG. Cholinergic receptor signaling modulates spontaneous fring of sinoatrial nodal cells via integrated effects on PKA-dependent Ca(2+) cycling and I(KACh). Am J Physiol Heart Circ Physiol. 2009;297:H949-H959. doi: 10.1152/ ajpheart.01340.2008.
46. Hua R, Adamczyk A, Robbins C, Ray G, Rose RA. Distinct patterns of constitutive phosphodiesterase activity in mouse sinoatrial node and atrial myocardium. PLoS One. 2012;7:e47652. doi: 10.1371/journal. pone.0047652.
47. Alig J, Marger L, Mesirca P, Ehmke H, Mangoni ME, Isbrandt D. Control of heart rate by cAMP sensitivity of HCN channels. Proc Natl Acad Sci USA. 2009;106:12189-12194. doi: 10.1073/pnas.0810332106.
48. Bers DM. Cardiac sarcoplasmic reticulum calcium leak: basis and roles in cardiac dysfunction. Annu Rev Physiol. 2014;76:107-127. doi: 10.1146/ annurev-physiol-020911-153308.
49. Neef S, Dybkova N, Sossalla S, Ort KR, Fluschnik N, Neumann K, Seipelt R, Schöndube FA, Hasenfuss G, Maier LS. CaMKII-dependent diastolic SR Ca2+ leak and elevated diastolic Ca2+ levels in right atrial myocardium of patients with atrial fibrillation. Circ Res. 2010;106:1134-1144. doi: 10.1161/CIRCRESAHA.109.203836.
50. Zoccarato A, Surdo NC, Aronsen JM, et al. Cardiac hypertrophy is inhibited by a local pool of cAMP regulated by phosphodiesterase 2. Circ Res. 2015;117:707-719. doi: 10.1161/CIRCRESAHA.114.305892.
51. Wagner M, Mehel H, Fischmeister R, El-Armouche A. Phosphodiesterase 2: anti-adrenergic friend or hypertrophic foe in heart disease? Naunyn Schmiedebergs Arch Pharmacol. 2016;389:1139-1141. doi: 10.1007/ s00210-016-1289-4.
52. Perera RK, Sprenger JU, Steinbrecher JH, Hübscher D, Lehnart SE, Abesser M, Schuh K, El-Armouche A, Nikolaev VO. Microdomain switch of cGMP-regulated phosphodiesterases leads to ANP-induced augmentation of β-adrenoceptor-stimulated contractility in early cardiac hypertrophy. Circ Res. 2015;116:1304-1311. doi: 10.1161/ CIRCRESAHA.116.306082.
53. Zhang M, Takimoto E, Lee DI, Santos CX, Nakamura T, Hsu S, Jiang A, Nagayama T, Bedja D, Yuan Y, Eaton P, Shah AM, Kass DA. Pathological cardiac hypertrophy alters intracellular targeting of phosphodiesterase type 5 from nitric oxide synthase-3 to natriuretic peptide signaling. Circulation. 2012;126:942-951. doi: 10.1161/CIRCULATIONAHA.112.090977.
54. Fischmeister R, Castro LR, Abi-Gerges A, Rochais F, Jurevicius J, Leroy J, Vandecasteele G. Compartmentation of cyclic nucleotide signaling in the heart: the role of cyclic nucleotide phosphodiesterases. Circ Res. 2006;99:816-828. doi: 10.1161/01.RES.0000246118.98832.04.
55. Zaccolo M, Movsesian MA. cAMP and cGMP signaling cross-talk: role of phosphodiesterases and implications for cardiac pathophysiology. Circ Res. 2007;100:1569-1578. doi: 10.1161/CIRCRESAHA.106.144501.
56. McMurray JJ, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, Rouleau J, Shi VC, Solomon SD, Swedberg K, Zile MR; PARADIGM-HF Committees and Investigators. Dual angiotensin receptor and neprilysin inhibition as an alternative to angiotensin-converting enzyme inhibition in patients with chronic systolic heart failure: rationale for and design of the Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trial (PARADIGM-HF). Eur J Heart Fail. 2013;15:1062-1073. doi: 10.1093/eurjhf/hft052.
57. McMurray JJ, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, Rouleau JL, Shi VC, Solomon SD, Swedberg K, Zile MR; PARADIGM-HF Investigators and Committees. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014;371:993-1004. doi: 10.1056/NEJMoa1409077.
58. Kuhn M. Cardiology: a big-hearted molecule. Nature. 2015;519:416-417. doi: 10.1038/nature14373.